DoJ Enlists Supporting Cast Against ‘Bad Actors’ On Supplement Stage
This article was originally published in The Tan Sheet
DoJ explores broader action and new avenues to rid the supplement market of noncompliant firms, Deputy Assistant Attorney General Olin says at a FDLI conference. CFSAN Deputy Director Michael Roosevelt says identification of unknown supplement ingredients is a 2016 priority.
You may also be interested in...
““The Tan Sheet” provides links to previous articles on many of the enforcements DoJ announced from its year-long sweep.
In a frank warning at a FDLI meeting, DoJ Director of Consumer Protection Michael Blume says the agency’s role is clear once it takes on a case investigated by FDA or FTC. Blume notes the dietary supplement category “has become something of an emphasis for us in the department.”
DoD suspends DMAA sales at military stores after regulators in Canada and New Zealand restricted access and as some U.S. firms change how they market and label the ingredient. These moves and the potential for an FDA review could lead to enforcement against DMAA similar to the 2004 ban against ephedra’s use in supplements.